Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Catalunya, Spain
Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Catalunya, Spain.
BMJ Case Rep. 2020 Aug 24;13(8):e233863. doi: 10.1136/bcr-2019-233863.
A 44-year-old woman diagnosed with a HER2 positive early breast cancer, receiving neoadjuvant treatment with paclitaxel and targeted agents, trastuzumab together with pertuzumab, presented to the emergency room with gait instability and upper right limb weakness. The neurological examination was compatible with cerebellar alteration showing right dissymmetry of the finger-nose and heel-knee manoeuvre. A head CT and a brain MRI were performed and negative. The electromyography showed alterations of the pyramidal pathway and somatosensory pathway. In order to determine the cause of the cerebellar affection, a lumbar puncture was performed. The cerebrospinal fluid analysis was non-specific, but the antineuronal anti-Yo antibody was positive, being diagnosed of a paraneoplastic cerebellar degeneration (PCD). A positron emission tomography CT ruled out metastatic disease. The patient completed four cycles of antiHER2 blockade and weekly paclitaxel, achieving a complete pathological response. One year later, she maintains a complete remission but the PCD still prevails.
一位 44 岁的女性,被诊断为 HER2 阳性早期乳腺癌,接受新辅助治疗,包括紫杉醇和靶向药物曲妥珠单抗联合帕妥珠单抗。她因步态不稳和右上肢体无力就诊于急诊。神经系统检查符合小脑改变,表现为右侧指鼻试验和跟膝胫试验不对称。头部 CT 和脑部 MRI 未见异常。肌电图显示锥体束和体感通路改变。为了确定小脑病变的原因,进行了腰椎穿刺。脑脊液分析无特异性,但抗神经元抗 Yo 抗体阳性,诊断为副肿瘤性小脑变性(PCD)。正电子发射断层扫描 CT 排除了转移性疾病。患者完成了四个周期的抗 HER2 阻断和每周紫杉醇治疗,达到完全病理缓解。一年后,她仍处于完全缓解期,但 PCD 仍存在。